Skip to main content
. 2022 Dec 5;46(2):109–120. doi: 10.1007/s40264-022-01258-0

Fig. 2.

Fig. 2

Schematic representation of 79 and 48 signals supported by at least two or three features. Each node is labeled after the features invoked in clinical assessments of adverse drug reaction reports; linked nodes indicate features that co-occurred. In brackets, count of signals per feature. Excl. excluding